Your session is about to expire
← Back to Search
Pazopanib for Advanced or Refractory Cancer
Study Summary
This trial is studying the side effects and best dose of pazopanib hydrochloride for treating patients with solid tumors that have spread or are resistant to treatment. Samples of blood from patients will be studied to learn more about how the drug affects the body and how well patients respond to treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer can be measured by tests.I don't have stomach ulcers, bowel diseases, or recent severe stomach/intestine issues.You are currently experiencing a serious wound, ulcer, bone fracture, or bleeding disorder. You have a history of abnormal bleeding or hemoptysis (coughing up blood) within the past 8 weeks. You have poorly controlled depression or anxiety, or have had suicidal thoughts within the past 6 months. You are taking warfarin, but not low molecular weight heparin. You are HIV-positive and receiving combination antiretroviral therapy.My blood clotting time is near normal and I'm not on warfarin.My heart's electrical cycle is longer than normal or I'm on medication that can extend it.My blood clotting time is near normal and I'm not on warfarin.I can swallow and absorb pills without any issues.My blood clotting time is within normal limits and I'm not on warfarin.My cancer cannot be treated with surgery or other standard treatments.My blood clotting time is within normal limits and I'm not on warfarin.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.My kidney function, measured by creatinine levels or clearance, is within the required range.Your platelet count is at least 100,000 per microliter.My potassium levels are mostly stable.My cancer cannot be cured by standard treatments.There is a known treatment that could cure or extend my life.I agree to give blood samples for drug level checks and genetic studies.My calcium levels are mostly normal.You are expected to live for at least 3 more months.My cancer can be measured by tests or scans.I am fully active or have some restrictions but can still care for myself.Your AST (a liver enzyme) level is not more than 2.5 times the upper limit of normal (ULN).You cannot participate in the study if you are pregnant, breastfeeding, or not willing to use contraception. You also cannot be receiving other chemotherapy, radiation therapy, or experimental treatments. If you have any severe illnesses or diseases that could interfere with the study, you cannot participate. If you have a weakened immune system, are taking certain medications, or have had certain types of cancer in the past, you may not be eligible. Additionally, if you have been taking mitotane in the last 6 months, you cannot participate.Your direct bilirubin levels are not more than 1.5 times the normal limit. If you have Gilbert's syndrome and high indirect bilirubin levels, you can still participate.My kidney function, measured by creatinine levels or clearance, is within the required range.My magnesium levels are not severely low or high.Your hemoglobin levels must be at least 8.0 g/dL.Your ANC (a type of white blood cell) count must be at least 1,500 cells per microliter.My blood phosphate levels are mostly normal.
- Group 1: Treatment (pazopanib hydrochloride)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the aggregate figure of participants involved in this research endeavor?
"Unfortunately, this trial is not enrolling participants at the moment. The clinical trial was first posted on March 19th 2012 and last updated June 28th 2022. Fortunately, there are currently 17 studies actively admitting patients with solid neoplasms as well as 24 trials for Pharmacological Study that have open enrollment periods."
What other laboratory experiments have explored the efficacy of pharmacological treatments?
"Initially conducted at the University of Texas MD Anderson Cancer Center in 2011, the Pharmacological Study has now seen 750 successful trials. Currently there are 24 enrolment sites across Rochester, Minnesota that are actively recruiting participants for new research studies."
Is this medical experiment enrolling participants at present?
"Unfortunately, the recruitment period for this clinical trial has ended. Initially posted on March 19th 2012 and most recently amended on June 28th 2022, there are no further openings available. However, if you are seeking alternative studies to join there are presently 17 trials searching for participants with solid neoplasms and 24 Pharmacological Study trials actively recruiting patients."
Has Pharmacological Study been approved by the FDA?
"Given that this is a Phase 1 trial, meaning there are only limited data supporting efficacy and safety of the pharmacological study, our team at Power has assigned it a score of 1."
Is this a groundbreaking research endeavor?
"Pharmacological Study has been under examination since 2011, when Novartis sponsored its first trial with 180 participants. After achieving Phase 2 drug approval in the years following, 24 active studies have now taken form across 608 cities and 23 countries."
Share this study with friends
Copy Link
Messenger